HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin

Authors

• R. Hattin
• A. Hussain
• H. Aboaid
• S. Schauer
• T. Schlesinger
• R. Twells
• K. Aharonian
• R. Parto
• R. Rahmani
• C. Lambert-Swainston
• D. T. Jones
• R. Srinivasmurthy
• Kyaw Z. Thein, Touro University NevadaFollow
• T. W. Htut

Roles

Author

Document Type

Article

Publication Date

1-1-2025

Publication Title

Journal of the National Comprehensive Cancer Network

DOI

10.6004/jnccn.2024.7313

Recommended Citation

Hattin, R., Hussain, A., Aboaid, H., Schauer, S., Schlesinger, T., Twells, R., Aharonian, K., Parto, R., Rahmani, R., Lambert-Swainston, C., Jones, D. T., Srinivasmurthy, R., Thein, K. Z., & Htut, T. W. (2025). HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin. Journal of the National Comprehensive Cancer Network, 23 (3.5), Article HSR25-143. https://doi.org/10.6004/jnccn.2024.7313